Calidi Biotherapeutics, Inc.
CLDI
$0.18
$0.00-0.05%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.50M | 10.61M | 10.99M | 11.53M | 12.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.24M | 19.80M | 19.98M | 20.09M | 21.78M |
| Operating Income | -20.24M | -19.80M | -19.98M | -20.09M | -21.78M |
| Income Before Tax | -20.05M | -20.13M | -20.03M | -20.03M | -22.20M |
| Income Tax Expenses | 15.00K | 20.00K | 9.00K | 13.00K | 14.00K |
| Earnings from Continuing Operations | -20.06 | -20.15 | -20.04 | -20.05 | -22.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 157.00K | 205.00K | 188.00K | 142.00K | 66.00K |
| Net Income | -19.91M | -19.95M | -19.85M | -19.90M | -22.14M |
| EBIT | -20.24M | -19.80M | -19.98M | -20.09M | -21.78M |
| EBITDA | -18.01M | -17.60M | -17.78M | -17.95M | -19.63M |
| EPS Basic | -6.97 | -9.62 | -15.17 | -29.93 | -52.11 |
| Normalized Basic EPS | -3.63 | -5.25 | -9.43 | -16.31 | -30.17 |
| EPS Diluted | -6.97 | -9.62 | -15.17 | -29.93 | -52.11 |
| Normalized Diluted EPS | -3.63 | -5.25 | -9.43 | -16.31 | -30.17 |
| Average Basic Shares Outstanding | 17.16M | 11.31M | 7.06M | 4.63M | 2.67M |
| Average Diluted Shares Outstanding | 17.16M | 11.31M | 7.06M | 4.63M | 2.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |